טוען...
Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma
Background/Aim: Trabectedin is a synthetic antineoplastic agent approved for advanced soft tissue sarcoma (STS) in Japan. The aim of this study was to evaluate the efficacy and safety of the Japan-approved dose of trabectedin for advanced STS. Patients and Methods: We retrospectively reviewed 38 pat...
שמור ב:
| הוצא לאור ב: | In Vivo |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
International Institute of Anticancer Research
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6755008/ https://ncbi.nlm.nih.gov/pubmed/31471412 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11644 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|